1. Latar belakang klinis
Gambaran penyakit
Uraian berikut tersedia dalam bahasa Inggris.
Obesity is a chronic, relapsing, progressive disease defined by excess adiposity that impairs health, conventionally indexed by a body-mass index (BMI) of 30 kg/m2 or higher, with lower ethnicity-adjusted Asian cut-points of 25 to 27 kg/m2 reflecting higher cardiometabolic risk at a given BMI. It is not simply a lifestyle state but a dysregulation of energy homeostasis driven by hypothalamic, gut-hormone (including GLP-1) and adipose-tissue signalling, with strong genetic and obesogenic-environment contributions. Pathophysiologically, expanded and ectopic fat promotes chronic low-grade inflammation, insulin resistance, dyslipidaemia and hypertension, mechanistically linking obesity to type 2 diabetes, atherosclerotic cardiovascular disease, non-alcoholic fatty liver disease, obstructive sleep apnoea, osteoarthritis and several cancers (WHO 2024). Clinically it matters as a modifiable upstream driver of the non-communicable disease burden: even modest, sustained weight loss of 5 to 15% measurably improves glycaemia, blood pressure and cardiovascular risk, yet lifestyle-only approaches rarely achieve or maintain this magnitude, defining a large therapeutic gap.
Epidemiologi
Uraian berikut tersedia dalam bahasa Inggris.
The global burden is vast and rising. WHO estimated that in 2022 about 2.5 billion adults were overweight, including over 890 million living with obesity, equating to roughly 43% of adults overweight and 16% with obesity, with obesity prevalence more than doubling since 1990 (WHO 2024). The GBD 2021 forecasting study estimated that 2.11 billion adults (about 1.00 billion men and 1.11 billion women) had overweight or obesity in 2021, projected to reach 3.80 billion by 2050 (GBD 2021 Obesity Collaborators 2025); high BMI was associated with an estimated 3.71 million deaths and 128.5 million DALYs in 2021 (Ng et al., eClinicalMedicine 2024). In Indonesia, Riskesdas documented adult obesity (BMI >=27) rising from 10.5% (2007) to 14.8% (2013) and 21.8% (2018), higher in women (29.3%) than men (14.5%), with central obesity around 31% and provincial peaks such as North Sulawesi (about 30%) (Kemenkes Riskesdas 2018). With an adult population exceeding 190 million, this implies tens of millions affected, concentrated in urban and higher-income strata, and high BMI ranks among the leading risk factors for death and disability nationally, underpinning Indonesia's surging type 2 diabetes and cardiovascular burden.
Terapi standar saat ini
Uraian berikut tersedia dalam bahasa Inggris.
Standard care begins with structured lifestyle modification, namely reduced-calorie diet, increased physical activity and behavioural support, typically delivered within tiered weight-management services internationally and escalating to multidisciplinary specialist care. Pharmacotherapy is added when lifestyle alone is insufficient. In Indonesia, the Kemenkes obesity guideline for primary health care (2021) and PB PAPDI/PERKENI guidance endorse lifestyle-first management, with orlistat 120 mg three times daily and the GLP-1 receptor agonist liraglutide 3 mg as adjuncts, reserving surgery for severe cases (Kemenkes 2021). Limitations are substantial: lifestyle programmes are weakly resourced and rarely sustained; orlistat is poorly tolerated (gastrointestinal effects) with modest efficacy; liraglutide requires daily injection and is costly; and bariatric surgery is concentrated in a few tertiary centres. Community-level response rests on puskesmas counselling and Posbindu PTM screening. Critically, none of these agents is reimbursed under JKN, so most pharmacological treatment is self-financed, restricting access to affluent urban patients.
Status regulasi dan penjaminan
Uraian berikut tersedia dalam bahasa Inggris.
The US FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management on 4 June 2021, the first new anti-obesity agent since 2014 (FDA 2021), followed by EMA marketing authorisation in 2022 and a positive NICE recommendation in TA875 (March 2023), which restricts use to specialist weight-management services for a maximum of two years (NICE 2023). It is indicated for adults with BMI >=30, or >=27 with a weight-related comorbidity, alongside diet and physical activity. In Indonesia, BPOM has registered Wegovy for weight management in adults, with public assessment reports documenting approval activity across 2024 to 2025, making it the only BPOM-approved injectable anti-obesity GLP-1 of its class (BPOM 2024). Critically, anti-obesity medicines including semaglutide are not listed in the Formularium Nasional (Fornas) and are therefore not reimbursed under JKN/BPJS Kesehatan; access is via private prescription and full out-of-pocket payment, a key affordability and equity constraint. No Indonesian HTA appraisal has yet been published.
2. Hasil kasus dasar
| Strategi | Biaya terdiskonto | QALY terdiskonto | Tahun hidup |
|---|---|---|---|
| Semaglutid 2,4 mg per minggu disertai program pengelolaan berat badan | Rp 140,2 juta | 16,134 | 33,25 |
| program pengelolaan berat badan dengan diet, latihan fisik, dan dukungan perilaku | Rp 71,7 juta | 15,362 | 31,71 |
| Selisih | Rp 68,5 juta | 0,772 | - |
3. Analisis probabilistik
- Simulasi probabilistik (500 sampel)
- Kasus dasar
4. Analisis sensitivitas
- Parameter pada nilai rendah
- Parameter pada nilai tinggi
5. Analisis skenario
| Skenario | Selisih QALY | Selisih biaya | Rasio per QALY |
|---|---|---|---|
| Base case (40 yr) | 0,772 | Rp 68,5 juta | Rp 88,8 juta |
| 5-year horizon | 0,028 | Rp 84,1 juta | Rp 3,0 miliar |
| 10-year horizon | 0,078 | Rp 80,9 juta | Rp 1,0 miliar |
| 20-year horizon | 0,267 | Rp 75,0 juta | Rp 281,3 juta |
| 0% discount rate | 1,661 | Rp 59,0 juta | Rp 35,5 juta |
| 5% discount rate | 0,491 | Rp 70,9 juta | Rp 144,5 juta |
| Full weight-regain after 2-year stop (diabetes/CV benefit reverts toward comparator) | 0,853 | Rp 67,1 juta | Rp 78,7 juta |
| Lower Asian BMI thresholds expand a lower-baseline-risk population (CV/diabetes onset x0.85) | 0,717 | Rp 69,5 juta | Rp 96,9 juta |
| High Indonesian prediabetes-to-diabetes progression (x1.4) | 0,911 | Rp 66,0 juta | Rp 72,5 juta |
| BPJS-negotiated price 40% below private list (semaglutide acquisition x0.6) | 0,772 | Rp 31,8 juta | Rp 41,2 juta |
6. Validasi model
Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0020%).
| Luaran pembanding | Prediksi model | Data terbit | Sumber |
|---|---|---|---|
| Annual progression from non-diabetic hyperglycaemia (prediabetes/IGT) to type 2 diabetes, lifestyle/comparator arm | 7,2% | 7,5% | Tabak AG et al. Prediabetes: a high-risk state for diabetes development. Lancet 2012;379(9833):2279-2290 - ~5-10%/yr IGT |
| Annual reversion of non-diabetic hyperglycaemia to normoglycaemia, lifestyle/comparator arm | 20,0% | 20,0% | STEP 1 placebo arm ~47.8% reverted to normoglycaemia at 68wk (Perreault L et al. Diabetes Care 2022;45:2396-2405); long- |
| Cumulative cardiovascular event incidence at 10 years from normal glucose tolerance, lifestyle/comparator arm | 6,0% | 8,0% | SELECT (Lincoff AM et al. NEJM 2023;389:2221-2232): primary MACE 8.0% in the placebo arm over mean ~3.3 yr in an obese/o |
7. Penyesuaian untuk Indonesia
Uraian berikut tersedia dalam bahasa Inggris.
- TA875 recommends semaglutide only within specialist weight-management services and for a maximum of 2 years; the Indonesia model mirrors this constrained pathway.
- Asian/Indonesian BMI risk thresholds (overweight >=23, obesity >=25-27) may justify lower BMI cut-offs than UK criteria, expanding the eligible pool but potentially lowering baseline absolute risk and worsening the ICER.
- A 6-month stopping rule for <5% weight loss should be implemented to preserve cost-effectiveness, consistent with STEP/TA875.
- Semaglutide is BPOM-registered (2024) but NOT in Fornas; current access is fully out-of-pocket, a major equity concern that HTA should adjudicate before any reimbursement.
- Budget impact is dominated by chronic, high-acquisition-cost treatment in a large, fast-growing obese population; eligibility narrowing (e.g., to high-CV-risk SELECT-like subgroups) materially improves affordability.